News | October 27, 2025
Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
This new facility strengthens Latin America as a collaborative hub
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
These findings follow positive Phase 3 results presented earlier this year
The new plant will manufacture high-quality Type I borosilicate glass tubing
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Subscribe To Our Newsletter & Stay Updated
